Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sangamo Therapeutics filings document regulatory, clinical, financial and corporate-status disclosures for a genomic medicine company developing gene therapy and genome-engineering technologies. Recent 8-K reports cover operating and financial results, clinical data from the STAAR study of isaralgagene civaparvovec, or ST-920, regulatory-pathway disclosures for Fabry disease, and material-event updates tied to the company's neurology pipeline.
The filing record also includes Nasdaq listing-compliance and delisting notices, SGMO common-stock registration information, finance leadership and officer-transition disclosures, and capital-structure information. These documents formalize the company's reported results, governance changes, securities status and clinical-regulatory events under SEC reporting rules.
Sangamo Therapeutics executive Gregory D. Davis, Head of Research & Technology, sold common stock in an open-market transaction. On April 22, 2026, he sold 69,827 shares of Sangamo Therapeutics common stock at a weighted-average price of $0.2534 per share, with individual trades ranging from $0.2533 to $0.2568. After this sale, Davis directly holds 115,284 shares of the company’s common stock.
Sangamo Therapeutics SVP-Chief Development Officer Nathalie Dubois-Stringfellow reported an open-market sale of Common Stock. She sold 345,942 shares on April 21, 2026 at a weighted-average price of $0.2578 per share in multiple trades ranging from $0.2533 to $0.2634.
Following this transaction, she directly holds 332,769 shares of Sangamo Therapeutics Common Stock. The filing does not report any derivative security exercises, indicating this was a straightforward share sale rather than an option-related transaction.
Filer submitted a Form 144 notifying a proposed sale of Common Stock. The notice lists securities held through E*TRADE from Morgan Stanley and documents multiple past acquisitions via ESPP purchases and vested restricted stock units. Examples include a 438,758 shares lot vested on 01/22/2026 and other grants on 02/25/2025 and 02/24/2026.
Sangamo Therapeutics senior vice president and chief development officer Nathalie Dubois-Stringfellow received a grant of stock options covering 800,000 shares of common stock. The options have an exercise price of $0.2601 per share and expire on March 31, 2036.
One quarter of the options will vest on the first anniversary of the grant date, with the remaining options vesting in 24 equal monthly installments, contingent on her continued service under the company’s 2018 equity incentive plan.
Sangamo Therapeutics Principal Accounting Officer Nikunj Jain received a grant of stock options as equity compensation. The award covers 225,000 options to buy common stock at an exercise price of $0.2601 per share, expiring on March 31, 2036.
One quarter of the options vest on the first anniversary of the grant date, and the remaining options vest in 24 equal monthly installments, subject to Mr. Jain’s continuous service and the terms of the company’s 2018 equity incentive plan. No open‑market share purchases or sales were reported in this filing.
Sangamo Therapeutics reported that Head of Research & Technology Gregory D. Davis received a new stock option grant. The award covers 225,000 stock options for common shares at an exercise price of $0.2601 per share, expiring on March 31, 2036.
One-quarter of the options will vest on the first anniversary of the grant, with the remaining options vesting in 24 equal monthly installments, contingent on his continued service under the company’s 2018 equity incentive plan. After this grant, he holds 225,000 derivative securities directly.
Sangamo Therapeutics reported that its President, CEO and Director, Sandy Macrae, received a grant of stock options covering 2,500,000 shares of common stock. The options have an exercise price of $0.2601 per share and expire on March 31, 2036.
According to the vesting terms, one-quarter of the option shares will vest and become exercisable on the first anniversary of the grant date, with the remaining shares vesting in 24 equal monthly installments after that, subject to Dr. Macrae’s continuous service and the provisions of the company’s 2018 Equity Incentive Plan.
Sangamo Therapeutics reported that SVP and Chief Legal Officer Scott B. Willoughby received a grant of stock options covering 800,000 shares of common stock. The options have an exercise price of $0.2601 per share and expire on March 31, 2036.
These options were granted as compensation and do not represent an open-market purchase or sale. One quarter of the options will vest after one year from the grant date, with the remaining shares vesting in 24 equal monthly installments, contingent on his continued service under the company’s 2018 equity incentive plan.
Sangamo Therapeutics’ annual report highlights both scientific progress and severe financial strain. The company focuses on zinc finger–based genomic medicines for neurologic diseases, including ST-503 for chronic neuropathic pain and ST-506 for prion disease, plus a strong AAV capsid platform (STAC-BBB) licensed to major partners.
Sangamo reports positive Phase 1/2 data for its Fabry gene therapy isaralgagene civaparvovec, including favorable kidney function slopes and quality-of-life gains, and has begun a rolling BLA submission under the FDA’s Accelerated Approval pathway. However, management states there is substantial doubt about its ability to continue as a going concern, warning it needs substantial near-term funding and may have to cease operations or seek U.S. bankruptcy protection.
The company has received significant collaboration revenue and could earn large future milestones, but also notes ongoing Nasdaq listing noncompliance, potential delisting, high dilution risk, and continued operating losses with no approved products.